Healthcare

SB 191 establishes a state-run pilot program for psychedelic-assisted therapy using MDMA and psilocybin, effective July 1, 2026. It directly affects qualified patients in Connecticut who are 18+ and meet specific criteria (veterans, retired first responders, or healthcare workers), providing them access to therapy administered by a state-selected medical school. The program requires federal FDA approval under 21 CFR 312 for research purposes and will terminate once MDMA/psilocybin receive DEA approval for medical use. The bill repeals an existing statute and creates a structured framework for this therapeutic pilot program.

This bill establishes new consumer protections for long-term care insurance policies in Connecticut, affecting insurance companies, policyholders, and state agencies. It requires the Office of Policy and Management to create an outreach program educating consumers about long-term care options, financing, and asset protection rules. The bill mandates that insurance policies must offer home and community-based services, include inflation protection, and cannot tie executive compensation to rate increases. Additionally, insurers must maintain a minimum 60% loss ratio, and any premium increases of 20% or more must be spread over at least three years.

HB 5044 establishes Connecticut's official vaccine standards for children and infants, requiring the Commissioner of Public Health to create and maintain a standard of care based on CDC and medical association guidelines. This standard, posted online, will guide vaccination schedules and safety protocols, and must be updated as needed. The bill also mandates a state immunization program that provides free vaccines to healthcare providers for children, distributes vaccination schedules to parents at hospital discharge, and develops outreach to help children who fall behind on immunizations. It directly affects children (especially infants), healthcare providers, hospitals, and public health departments. The program must use available state and federal funds to support these services without creating new state regulations.

This bill requires health insurance plans and Medicaid to cover a twelve-month supply of prescription contraception and hormone therapy at one time, effective January 1, 2027. It applies to individuals with private insurance and Medicaid enrollees, allowing them to receive up to one year of medication and administration supplies in a single dispensation unless they or their provider request less. The law excludes certain drugs like glucagon-like peptide-1 agonists from hormone therapy coverage and permits health plans to use standard drug management rules, including limiting refills near the end of a plan year if the full supply was already provided.